Azenta, Inc. (FRA:BA3)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.40B +19.9% |
| Revenue (ttm) | 537.27M +4.8% |
| Net Income | -107.57M |
| EPS | -2.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 63.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 31.60 |
| Previous Close | 30.60 |
| Day's Range | 28.40 - 31.60 |
| 52-Week Range | 13.50 - 34.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sampl... [Read more]
Financial Performance
In fiscal year 2025, Azenta's revenue was $593.82 million, an increase of 3.55% compared to the previous year's $573.45 million. Losses were -$55.76 million, -66.18% less than in 2024.
Financial numbers in USD Financial StatementsNews
Azenta reaffirms Q4 previous revenue view
The Company is reaffirming its Q4 total revenue guidance previously issued on August 4: total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition…
Azenta appoints Martin Madaus as interim President and CEO
Azenta (AZTA) announced that current member of the Board of Directors Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer…
AZENTA ANNOUNCES LEADERSHIP TRANSITION
Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azent...
Azenta price target raised to $35 from $28 at Evercore ISI
Evercore ISI raised the firm’s price target on Azenta (AZTA) to $35 from $28 and keeps an Outperform rating on the shares.
Azenta Earnings Call Transcript: Q3 2026
Q3 revenue and profitability exceeded expectations, driven by strong recurring revenue in biorepositories, C&I, and Multiomics, especially in Europe and China. FY 2026 guidance was raised, but the outlook remains cautious due to uneven demand and ongoing challenges in Sanger Sequencing and Automated Stores.
Azenta Earnings release: Q3 2026
Azenta released its Q3 2026 earnings on August 5, 2026, summarizing the period's financial results.
Azenta Slides: Q3 2026
Azenta has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 5, 2026.
Azenta Quarterly report: Q3 2026
Azenta has published its Q3 2026 quarterly earnings report on August 5, 2026.
Azenta sees FY26 adjusted EBITDA $59M-$62M
Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range approximately between flat to up…
Azenta reports Q3 adjusted cont ops EPS 16c, consensus 10c
Reports Q3 revenue $161M, consensus $149.23M. “Despite an uneven and challenging market backdrop, our third quarter results exceeded our expectations, with continued strength in our recurring revenue ...
Azenta sees Q4 adjusted EBITDA 20M-$23M
Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits…
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market...
Azenta completes sale of B Medical Systems
Azenta (AZTA) announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema. The transaction was originally announced on December 29, 2025 and closed on…
Azenta Completes Sale of B Medical Systems
BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.
Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
BURLINGTON, Mass., May 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, demonstrating continued pr...
Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Azenta, Inc. (NASDAQ: AZTA). The investigation focuses on Azenta's executiv...
Azenta Earnings Call Transcript: Q2 2026
Q2 organic revenue declined 3% year-over-year with margin pressures from lower North America volumes and execution gaps. Fiscal 2026 guidance was revised downward, but recurring revenue streams and European/Asian growth remain strong. Leadership and operational changes are underway to address challenges.
Azenta Earnings release: Q2 2026
Azenta released its Q2 2026 earnings on May 6, 2026, summarizing the period's financial results.
Azenta Slides: Q2 2026
Azenta has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Azenta Quarterly report: Q2 2026
Azenta has published its Q2 2026 quarterly earnings report on May 6, 2026.
Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 million FY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared...
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the mar...
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026.
Azenta price target lowered to $35 from $45 at Evercore ISI
Evercore ISI lowered the firm’s price target on Azenta (AZTA) to $35 from $45 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…